Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Share-based Compensation (2020 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Share-based Compensation for 7 consecutive years, with $359255.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 5.9% year-over-year to $359255.0, compared with a TTM value of $1.3 million through Dec 2025, down 6.58%, and an annual FY2025 reading of $1.3 million, down 5.94% over the prior year.
  • Share-based Compensation was $359255.0 for Q4 2025 at Neuroone Medical Technologies, roughly flat from $358560.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.4 million in Q2 2021 and bottomed at $203072.0 in Q4 2021.
  • Average Share-based Compensation over 5 years is $356435.8, with a median of $312646.0 recorded in 2023.
  • The sharpest move saw Share-based Compensation tumbled 82.24% in 2022, then skyrocketed 50.18% in 2024.
  • Year by year, Share-based Compensation stood at $203072.0 in 2021, then soared by 47.82% to $300181.0 in 2022, then rose by 2.82% to $308638.0 in 2023, then rose by 9.91% to $339224.0 in 2024, then rose by 5.9% to $359255.0 in 2025.
  • Business Quant data shows Share-based Compensation for NMTC at $359255.0 in Q4 2025, $358560.0 in Q3 2025, and $316654.0 in Q2 2025.